NCT01578330View on ClinicalTrials.gov

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Multiple SclerosisRelapsing-Remitting
Interventions
DRUG

Fingolimod

Fingolimod 0.5mg orally once a day without food.

Trial Locations (11)

16059

Novartis Investigative Site, Bursa

34098

Novartis Investigative Site, Fatih / Istanbul

34394

Novartis Investigative Site, Mecidiyekoy/Istanbul

34662

Novartis Investigative Site, Altunizade

34668

Novartis Investigative Site, Uskudar / Istanbul

35040

Novartis Investigative Site, Izmir

41380

Novartis Investigative Site, Kocaeli

55139

Novartis Investigative Site, Atakum / Samsun

61080

Novartis Investigative Site, Trabzon

06100

Novartis Investigative Site, Ankara

06500

Novartis Investigative Site, Ankara

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY